Pan-Immune-Inflammation Value as a Prognostic Biomarker for Hepatocellular Carcinoma Patients Undergoing Hepatectomy

Hongyuan Fu,1 Yubo Wang,2 Bangde Xiang1 1Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Province, People’s Republic of China; 2The Second Clinical Medical College of Guangxi Medical University, Nanning, Guangxi Province, People’s Republic of ChinaCorrespondence: Bangde Xiang, Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, No. 71 hedi Road, Qingxiu District, Nanning, Guangxi Province, 530021, People’s Republic of China, Email [email protected]: Hepatocellular carcinoma (HCC) poses a substantial threat to global health, characterized by its high incidence and mortality rates. This research aims to assess the prognostic value of a systematic serum inflammation index, the pan-immune-inflammation value (PIV), in patients with HCC who have undergone hepatectomy.Patients and Methods: A total of 1764 HCC patients who underwent surgery were included in the study. These patients were divided into two groups based on the median PIV value. The Cox regression model was utilized to ascertain the independent risk factors that influence the prognosis of patients. A PIV-based nomogram was constructed and its performance was evaluated by the C-index, calibration curve, ROC curve, and DCA curve. Finally, a comparison was made between the nomogram and existing staging models.Results: Patients with elevated PIV exhibited diminished OS and RFS compared to those with lower PIV. Univariate and multivariate Cox analyses revealed that PIV is an independent predictor of prognosis. The PIV-based nomogram demonstrated excellent discrimination, calibration, and clinical net benefit. The proposed nomogram outperformed the other existing staging systems, as evidenced by a higher AUC value.Conclusion: PIV exhibits potential as a prognostic factor for both OS and RFS in patients with HCC who have undergone hepatectomy. The PIV-based nomogram can serve as an additional tool in conjunction with the existing liver cancer staging system, thereby facilitating more personalized treatment decisions for clinicians.Keywords: hepatocellular carcinoma, pan-immune- inflammation value, hepatectomy, prognosis